Outcome of NHL Patients According to Risk Groups Defined by TNF/LT Polymorphic Haplotype Status
| Risk Group . | No. of High-Producer Alleles . | Distribution of Patients (%) . | Complete Response Rate (%) . | Progression-Free Survival (%) . | Overall Survival (%) . | ||
|---|---|---|---|---|---|---|---|
| 2-yr Rate (SE) . | 4-yr Rate (SE) . | 2-yr Rate (SE) . | 4-yr Rate (SE) . | ||||
| All patients enrolled in the study (n = 273) | 61 | 57.2 ± 3.2 | 37.0 ± 3.8 | 80.8 ± 2.5 | 68.4 ± 3.6 | ||
| Low | 0 or 1 | 197 (72%) | 66 | 61.6 ± 3.7 | 42.7 ± 4.6 | 83.3 ± 2.8 | 71.9 ± 4.1 |
| High | 2-4 | 76 (28%) | 49 | 45.8 ± 6.1 | 23.3 ± 6.3 | 74.1 ± 5.3 | 58.7 ± 7.7 |
| Patients with large cell lymphoma (n = 126) | 69 | 57.4 ± 4.8 | 44.0 ± 6.5 | 69.2 ± 4.6 | 59.6 ± 6.3 | ||
| Low | 0 or 1 | 84 (67%) | 74 | 62.4 ± 5.7 | 55.3 ± 6.9 | 70.4 ± 5.8 | 63.8 ± 6.8 |
| High | 2-4 | 42 (33%) | 61 | 47.7 ± 8.5 | 14.3 ± 11.7 | 67.1 ± 8.0 | 46.7 ± 15.0 |
| Risk Group . | No. of High-Producer Alleles . | Distribution of Patients (%) . | Complete Response Rate (%) . | Progression-Free Survival (%) . | Overall Survival (%) . | ||
|---|---|---|---|---|---|---|---|
| 2-yr Rate (SE) . | 4-yr Rate (SE) . | 2-yr Rate (SE) . | 4-yr Rate (SE) . | ||||
| All patients enrolled in the study (n = 273) | 61 | 57.2 ± 3.2 | 37.0 ± 3.8 | 80.8 ± 2.5 | 68.4 ± 3.6 | ||
| Low | 0 or 1 | 197 (72%) | 66 | 61.6 ± 3.7 | 42.7 ± 4.6 | 83.3 ± 2.8 | 71.9 ± 4.1 |
| High | 2-4 | 76 (28%) | 49 | 45.8 ± 6.1 | 23.3 ± 6.3 | 74.1 ± 5.3 | 58.7 ± 7.7 |
| Patients with large cell lymphoma (n = 126) | 69 | 57.4 ± 4.8 | 44.0 ± 6.5 | 69.2 ± 4.6 | 59.6 ± 6.3 | ||
| Low | 0 or 1 | 84 (67%) | 74 | 62.4 ± 5.7 | 55.3 ± 6.9 | 70.4 ± 5.8 | 63.8 ± 6.8 |
| High | 2-4 | 42 (33%) | 61 | 47.7 ± 8.5 | 14.3 ± 11.7 | 67.1 ± 8.0 | 46.7 ± 15.0 |